Aytu Biopharma Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2026 to a ratio of 1.99, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Aytu Biopharma Inc in Jun 30 2026 quarter, has decreased to 183 days, compared to 196 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 499 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1980 to 3112.

What is Receivable Turnover Ratio?
What is Aytu Biopharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AYTU Receivables Turnover Ratio	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Receivable Change	-26.88 %	-31.64 %	31.92 %	43.46 %	22.91 %
Y / Y Revenue Change	-0.91 %	-34.86 %	-7.36 %	-17.51 %	-14.03 %
Receivable Turnover Ratio (TTM)	1.99	1.86	1.88	2.04	2.31
AYTU's Total Ranking	# 3112	# 1980	# 1817	# 1845	# 2930
Accounts Receivable average collection period days	184	197	194	179	158
Seq. Receivable Change	-6.98 %	-21.4 %	-6.23 %	6.64 %	-13.04 %
Seq. Revenue Change	38.86 %	-20.69 %	10.91 %	-18.88 %	-8.72 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 162
Healthcare Sector	# 500
Overall Market	# 3112

Receivable Turnover Ratio Statistics
High	Average	Low
14.58	4.76	1.86
(Jun 30 2016)		(Mar 31 2026)

AYTU Company Profile • Back to AYTU Efficiency Comparisons • Compare AYTU Receivables Turnover Ratio to its Competitors

Financial Statements
Aytu Biopharma Inc's Accounts Receivable	$ 23 Millions	Visit AYTU's Balance sheet
Aytu Biopharma Inc's Sales TTM	$ 56 Millions	Visit AYTU's Income Statement
Sources of AYTU's Revenues		Visit AYTU's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
AYTU's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
AYTU's Growth Rates	AYTU's Roa	AYTU's Inventory Turnover Ratio	AYTU's Dividend Comparisons
AYTU's Profitability Ratios	AYTU's Roi	AYTU's Asset Turnover Ratio	AYTU's Dividend Growth
AYTU's Valuation Ratios	AYTU's Roe	AYTU's Financial Strength Ratios	AYTU's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Ufp Technologies Inc	6.65	$ 632.042 Millions	$ 94.976 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Livanova Plc	6.62	$ 1,470.112 Millions	$ 222.035 Millions
Agilon Health Inc	6.61	$ 5,920.015 Millions	$ 895.120 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Beone Medicines Ltd	6.58	$ 6,128.238 Millions	$ 930.639 Millions
Embecta Corp	6.57	$ 1,019.700 Millions	$ 155.125 Millions
Editas Medicine Inc	6.57	$ 47.005 Millions	$ 7.156 Millions
Labcorp Holdings Inc	6.49	$ 14,348.000 Millions	$ 2,210.975 Millions
Intellia Therapeutics Inc	6.44	$ 59.506 Millions	$ 9.243 Millions
Cvrx inc	6.44	$ 60.164 Millions	$ 9.345 Millions
Schrodinger Inc	6.43	$ 259.035 Millions	$ 40.267 Millions
Baxter International Inc	6.43	$ 11,555.000 Millions	$ 1,798.000 Millions
Healthcare Services Group Inc	6.42	$ 1,864.594 Millions	$ 290.515 Millions
Verastem Inc	6.42	$ 87.526 Millions	$ 13.640 Millions
Haemonetics Corporation	6.42	$ 1,351.722 Millions	$ 210.662 Millions
Macrogenics Inc	6.41	$ 167.674 Millions	$ 26.170 Millions
Bruker Corporation	6.41	$ 3,498.900 Millions	$ 546.100 Millions
Adaptive Biotechnologies Corporation	6.38	$ 308.081 Millions	$ 48.254 Millions
Iradimed Corporation	6.38	$ 86.339 Millions	$ 13.533 Millions
Aquestive Therapeutics Inc	6.37	$ 54.087 Millions	$ 8.489 Millions
Zoetis Inc	6.32	$ 9,517.000 Millions	$ 1,506.750 Millions
Nuwellis Inc	6.28	$ 9.013 Millions	$ 1.435 Millions
Puma Biotechnology Inc	6.27	$ 231.244 Millions	$ 36.902 Millions
Absci Corp	6.24	$ 1.561 Millions	$ 0.250 Millions
Insulet Corporation	6.24	$ 3,053.400 Millions	$ 489.200 Millions

Date modified: 2026-09-26T08:02:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.